Clearstead Advisors’s Aktis Oncology AKTS Stock Holding History

Clearstead Advisors’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195	Buy	+6	New	+$123	﹤0.01%	3214

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Clearstead Advisors's AKTS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Aktis Oncology (AKTS) in Q2 2026: 6 shares worth $195. The stake represents ﹤0.01% of the portfolio and ranks #3214 among its holdings.

114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Clearstead Advisors held 6 shares of Aktis Oncology worth $195 as of Q2 2026.
Aktis Oncology was a new Clearstead Advisors position in Q2 2026.
Aktis Oncology made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3214 holding.
114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.